Title:Meta-analysis of the Relationship between Type 2 Diabetes Mellitus and
Renal Cancer Risk
Volume: 24
Issue: 7
Author(s): Yingxin Wang*, Ying Cao and Chenchen Zhu
Affiliation:
- Department of Ultrasound, The First Affiliated Hospital of Xinjiang Medical University, 830054, Xinjiang, People’s
Republic of China
Keywords:
Diabetes, cohort study, confidence intervals, renal cancer, renal cell carcinoma, hypoglycemic drugs, mortality.
Abstract:
Objective: This study aimed to investigate the relationship between type 2 diabetes
mellitus and the risk of renal cancer.
Methods: A search was carried out on PubMed, Embase, Web of Science, China Biology Medicine
disc (CBM), China National Knowledge Infrastructure (CNKI), Wanfang and other databases.
The search period was from 2000 to 2022. The two authors independently conducted literature
screening, extracted literature data, and then conducted a literature quality evaluation.
The type of study is a cohort study. Meta-analysis was carried out on the included literature
through Stata12.0 software, and the combined value was calculated with RR value and 95% confidence
interval. Subgroup analysis was carried out to explore the impact of different factors on
the overall results.
Results: A total of 10 articles were included. Through cohort study, the meta-analysis on the risk
of type 2 diabetes and renal cancer showed that the combined effect value Risk Ratio (RR) =
1.57 with 95% Confidence Intervals (CI) (1.36, 1.82) and P<0.05. The difference had a significant
impact, indicating that the risk of renal cancer in type 2 diabetes patients was 1.55 times
higher than that in non-type 2 diabetes patients. The subgroup analysis showed that the combined
effect value RR and 95% CI for men was 1.49 (1.26, 1.75), and the combined effect value
RR and 95% CI for women was 1.60 (1.35, 1.88), which was basically consistent.
Conclusion: Type 2 diabetes can significantly increase the risk of renal cell carcinoma, and the
former is a risk factor for the latter. It is suggested that multi-center studies with larger sample
sizes should be conducted in the future, and adjustments should be made according to the type of
diabetes, the source of the study population, the pathological type of renal cell carcinoma, the
use of hypoglycemic drugs, and other factors, to provide a reliable basis for the study of the relationship
between diabetes and renal cell carcinoma. At present, the specific mechanism of diabetes
increasing the risk of renal cell carcinoma and whether diabetes increases mortality due to
renal cell carcinoma is still unclear and needs further research.
